Can a Three-Pronged therapy reboot the brain after injury?
NCT ID NCT06704334
First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time
Summary
This trial explores whether combining two medications—ginkgo leaf dropping pills and huperzine A injection—with a non-invasive nerve stimulation therapy can improve cognitive function in adults who have lasting thinking and memory problems after a brain injury. Participants will receive the combined treatment, and researchers will measure changes in cognitive test scores. The goal is to see if this approach can help the brain recover and improve daily mental abilities.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ginkgo leaf dropping pills, huperzine A injection, and median nerve electrical stimulation
- What this could lead to
- If successful, this combination could offer a new way to help people regain cognitive function after a brain injury.
- What could go wrong
- This is a small, early-phase study, so results may not apply broadly. The treatments could have side effects or interactions, and the electrical stimulation may not be suitable for everyone.
Why investors are watching
Wanbangde Pharmaceutical Group is running a Phase 4 trial testing a combination of ginkgo leaf dropping pills, huperzine A injection, and median nerve electrical stimulation for cognitive impairment after brain injury. For a small company, this readout matters because it could validate a new use for existing products and open a path to a broader market. The trial has only 50 participants, so results will be preliminary but could still shape the company's pipeline.
If it works: A positive result could support a new indication for cognitive impairment, potentially expanding sales of the company's existing drugs. It might also attract partnership interest or regulatory attention for a larger confirmatory study.
If it fails: A negative or unclear result could stall the program and leave the company without a new growth driver. Small trials often fail to show clear benefit, and the company would need to decide whether to invest in a larger study.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Be over 18 years old * Residual cognitive impairment due to brain injury * No previous history of brain-related diseases except this one Exclusion Criteria: * The patient had severe underlying disease and unstable vital signs * The patient was complicated with consciousness disorder and could not cooperate with cognitive function assessment * Allergic to drugs or contraindications in drug use * There are contraindications of median nerve electrical stimulation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cognitive impairment after brain injury are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The Ganzhou City People's Hospital
RECRUITINGGanzhou, Jiangxi, 8112320, China